CLOVIS ONCOLOGY INC's ticker is CLVS and the CUSIP is 189464100. A total of 2 filers reported holding CLOVIS ONCOLOGY INC in Q1 2023. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2022 | $479 | -99.9% | 10,050 | +0.5% | 0.01% | +8.3% |
Q3 2022 | $477,000 | +23750.0% | 10,000 | +2757.1% | 0.01% | – |
Q2 2021 | $2,000 | 0.0% | 350 | 0.0% | 0.00% | – |
Q1 2021 | $2,000 | – | 350 | – | 0.00% | – |
Q4 2020 | $0 | – | 0 | – | 0.00% | – |
Q3 2020 | $0 | – | 0 | – | 0.00% | – |
Q2 2020 | $0 | – | 0 | – | 0.00% | – |
Q1 2020 | $0 | – | 0 | – | 0.00% | – |
Q4 2019 | $0 | -100.0% | 0 | -100.0% | 0.00% | – |
Q3 2019 | $1,000 | -75.0% | 190 | -24.0% | 0.00% | – |
Q4 2018 | $4,000 | -85.2% | 250 | -37.5% | 0.00% | -100.0% |
Q1 2018 | $27,000 | 0.0% | 400 | 0.0% | 0.00% | 0.0% |
Q4 2017 | $27,000 | -73.8% | 400 | -68.0% | 0.00% | -75.0% |
Q3 2017 | $103,000 | -22.0% | 1,250 | -11.0% | 0.00% | -33.3% |
Q2 2017 | $132,000 | -33.3% | 1,405 | -54.8% | 0.01% | -33.3% |
Q1 2017 | $198,000 | +9.4% | 3,110 | -23.7% | 0.01% | 0.0% |
Q4 2016 | $181,000 | -42.2% | 4,075 | -53.0% | 0.01% | -43.8% |
Q3 2016 | $313,000 | +281.7% | 8,675 | +44.6% | 0.02% | +220.0% |
Q2 2016 | $82,000 | +86.4% | 6,000 | +380.0% | 0.01% | +66.7% |
Q4 2015 | $44,000 | – | 1,250 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Palo Alto Investors LP | 3,997,826 | $10,834,000 | 0.69% |
Ikarian Capital, LLC | 1,112,669 | $3,016,000 | 0.45% |
Versant Venture Management, LLC | 101,855 | $276,000 | 0.15% |
Virtus ETF Advisers LLC | 60,836 | $165,000 | 0.06% |
EMFO, LLC | 21,500 | $58,000 | 0.05% |
QVT Financial LP | 505,000 | $1,369,000 | 0.05% |
QVT Financial LP | 505,000 | $1,369,000 | 0.05% |
PINNACLE ASSOCIATES LTD | 706,336 | $1,914,000 | 0.03% |
XTX Topco Ltd | 20,920 | $57,000 | 0.03% |
State of Wyoming | 25,419 | $69,000 | 0.03% |